041 | No quick wins: more jobs but littl...

Time for a new episode of Tomorrow! Today we’re unpacking the results the Allianz Pulse. For the seventh edition, we surveyed 6,000 people across six of Europe’s largest economies: Germany, France, Italy, Spain, Poland, and Austria, taking the pulse on future prospects, policymak ... Show More

The global economy has got that summertime, summertime sadness. Global GDP growth could hit the slowest pace since 2008 this year, outside of recession periods, according to our mid-year economic outlook for 2025-26. The US is expected to grow by +1.6%, helped by lower effective ... Show More

Time for a new episode of Tomorrow! Today, we’re diving into a crucial – but often overlooked – indicator of business health: Working Capital Requirements. WCR is the financial canary in the coal mine, revealing how efficiently companies are managing cash flows, inventories, and ... Show More

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More

Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.Why GLP-1 Drugs Are in Demand Competition Betw ... Show More

The late Steve Jobs of Apple said “I think the biggest innovation of the 21st century will be at the intersection of biology and technology, a new era is beginning”. If you want see how biotech can change the world of health, whilst potentially being capable of creating extraordi ... Show More

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some i ... Show More

Ozempic is a drug used to treat type 2 diabetes and obesity but social media influencers have now turned it into the most popular weight loss drug. Promotion of the drug has led to a shortage of supply with Australia's drugs regulator now investigating the matter. However, other ... Show More

WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the co ... Show More

Stocks jumping to start the week, as investors hope President Trump may be softening his stance on tariffs. If you can believe the bounce, and the sectors seeing the biggest gains. Plus One pharma company looking to tip the scales in the weight loss drug space. What the CEO of St ... Show More

"Pharmaceutical Breakthroughs: The Cutting Edge of Biotechnology" - In this episode, we dive deep into the revolutionary world of biotechnology and its transformative impact on pharmaceuticals. Discover how cutting-edge innovations are reshaping drug development, accelerating vac ... Show More

Send us a textThis week on The Less Stressed Life Podcast, I am excited and honored to be joined by Dr. Paul Anderson, a recognized educator and clinician in integrative and naturopathic medicine with a focus on complex chronic illness and cancer. In this episode, we get super ne ... Show More

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Susan Desmond-Hellmann is a physician and scientist whose remarkable career has spanned clinical medicine, oncology, biotech innovation, and global ... Show More